Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES LANTMÄNNEN IN CONNECTION WITH ISSUE OF PARTICIPATING DEBENTURES
Mandate

VINGE ADVISES LANTMÄNNEN IN CONNECTION WITH ISSUE OF PARTICIPATING DEBENTURES

November 14, 2014

Lantmännen co-operative association has published a prospectus in relation to an offer to subscribe for participating debentures. The offer, which amounts to a maximum amount of SEK 250 million, is primarily directed to Lantmännen’s members and full-time group employees in Sweden and a number of associations in the agricultural and food industry. Vinge advised Lantmännen in connection with the offer.

Vinge’s team consisted of partner Jesper Schönbeck and associates Joakim Hagberg, Tora Hansjons and Nils Fredrik Dehlin.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026